MCM
AXSM icon

Manchester Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Manchester Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$245 Buy
+1
New +$217 ﹤0.01% 1270
2021
Q3 		– Sell
-12
Closed -$1K – 1030
2021
Q2 		$1K Buy
+12
New +$720 ﹤0.01% 732

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Manchester Capital Management's AXSM Position: Q2 2026 in Review

Manchester Capital Management opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 1 share worth $245. The stake represents ﹤0.01% of the portfolio and ranks #1270 among its holdings. This is a return to the name: Manchester Capital Management previously reported a position in AXSM as recently as Q2 2021.

Manchester Capital Management first reported a position in AXSM in Q2 2021 and has held it in 2 quarters since. The position peaked at $1K in Q2 2021. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Manchester Capital Management held 1 share of Axsome Therapeutics worth $245 as of Q2 2026.
  • Axsome Therapeutics was a new Manchester Capital Management position in Q2 2026.
  • Axsome Therapeutics made up ﹤0.01% of Manchester Capital Management's portfolio in Q2 2026, its #1270 holding.
  • Manchester Capital Management first reported a position in Axsome Therapeutics in Q2 2021 and has held it in 2 quarters since.
  • Manchester Capital Management's Axsome Therapeutics position peaked at $1K in Q2 2021.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.